From the June 2017 issue of HealthCare Business News magazine
As our knowledge of cell and molecular biology increases, more imaging targets will become available. Even now, we are beginning to understand epigenetic regulatory mechanisms, all of which will be targetable by NN. In the coming century, we will also develop methods to restore the damaged nervous system. Neuroregeneration by regrowing axons and nerves, neurogenesis for regrowing dead or dying neurons by marshalling stem cells, either endogenous or engineered will all be part of our therapeutic armamentarium. These revolutionary therapeutic endeavors will be guided by the techniques of NN. The future is bright for NN.
About the author: Robert S. Miletich, M.D., Ph.D., FAAAS, is a scientist, clinician, teacher and administrator at the University at Buffalo. He is a professor of nuclear medicine, interim chair of the Department of Nuclear Medicine, residency program director of the Nuclear Medicine Residency and medical director of the Nuclear Medicine Technology Program. He is the author of 36 peer-reviewed papers, four reviews, nine book chapters, one book and 84 conference proceedings.Back to HCB News
Ad Statistics
Times Displayed: 2548
Times Visited: 12 Fast-moving cardiac structures have a big impact on imaging. Fujifilm’s SCENARIA View premium performance CT brings solutions to address motion in Coronary CTA while delivering unique dose saving and workflow increasing benefits.
